ArticleThe Journal of general virology2026
GTPase domain of porcine Mx1 protein interacts with the N protein of porcine deltacoronavirus to inhibit viral replication.
Article in The Journal of general virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine deltacoronavirus (PDCoV) is an emerging enteric pathogen that poses significant economic threats to the swine industry and carries potential zoonotic risk. However, the interactions between PDCoV and host innate immunity, particularly those involving interferon-stimulated genes (ISGs), remain poorly understood. Porcine myxovirus resistance protein 1 (pMx1), a well-characterized ISG with broad-spectrum antiviral activity, has not been investigated in the context of PDCoV infection. This study demonstrates that PDCoV infection upregulates endogenous pMx1 expression in porcine intestinal epithelial cells (IPEC-J2 and IPI-2I) through a type I interferon alpha-dependent pathway. Functional analyses further revealed that pMx1 exerts potent antiviral activity against PDCoV. Mechanistically, we identified a direct interaction between the pMx1 protein and the PDCoV nucleocapsid (N) protein and found the GTPase domain of pMx1 as the critical binding region. This finding was strongly supported by a predicted interaction complex structural model generated using AlphaFold 3, and the GTPase domain was shown to be indispensable for the antiviral function of pMx1. Furthermore, we identified a critical synergistic interaction between the PDCoV N protein and the viral RNA-dependent RNA polymerase - nonstructural protein 12, a core component of the replication-transcription complex. Co-immunoprecipitation assays demonstrated that pMx1 effectively disrupts this interaction, suggesting that pMx1 may inhibit viral genome replication by impairing the formation or stability of the viral replication complex. Collectively, our study elucidates the mechanism by which the pMx1 protein, as a host antiviral factor, inhibits PDCoV infection. These findings provide novel insights into the innate immune defence against coronaviruses and highlight the pMx1 gene as a promising host-derived antiviral factor with potential applications in antiviral therapeutics and genetic improvement strategies for PDCoV control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.